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Abstract
Background: Cannabinoids represent unique compounds for treating tumors, including astrocytomas. Whether CB1 and
CB2 receptors mediate this therapeutic effect is unclear.
Principal Findings: We generated astrocytoma subclones that express set levels of CB1 and CB2, and found that
cannabinoids induce apoptosis only in cells expressing low levels of receptors that couple to ERK1/2. In contrast,
cannabinoids do not induce apoptosis in cells expressing high levels of receptors because these now also couple to the
prosurvival signal AKT. Remarkably, cannabinoids applied at high concentration induce apoptosis in all subclones
independently of CB1,C B 2 and AKT, but still through a mechanism involving ERK1/2.
Significance: The high expression level of CB1 and CB2 receptors commonly found in malignant astrocytomas precludes the
use of cannabinoids as therapeutics, unless AKT is concomitantly inhibited, or cannabinoids are applied at concentrations
that bypass CB1 and CB2 receptors, yet still activate ERK1/2.
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Introduction
Cannabinoids produce the majority of their biological effects by
activating two receptors: CB1 and CB2. In healthy brain, CB1 is
expressed by neurons, astrocytes and neural progenitor cells,
whereas CB2 is only expressed by a small population of neurons
located in the brain stem [1,2]. Activation of CB1 and CB2
receptors regulates fundamental physiological processes, including
neurotransmission efficacy, astrocytic function, and the fate and
proliferation rate of neural progenitor cells [3,4]. Thus, because
these receptors regulate such fundamental physiological processes,
extensive effort has been invested toward understanding how
cannabinoid compounds activate CB1 and CB2 receptors, as well
as regulate the signal transduction mechanisms they couple to,
with the goal of developing novel therapeutics to treat various
neuropathologies [5,6].
One of the most promising therapeutic uses of cannabinoids is
linked to their ability to induce apoptosis in tumors, including in
astrocytoma subclones grown either in vitro, subcutaneously in
immunodeficient mice, or intracranially in rats [7,8]. In fact, these
data were so compelling that one clinical trial has already been
carried-out, in which patients afflicted with recurrent astrocytomas
(grade IV) were treated with cannabinoids stereotactically injected
directly into the mass of the malignant tumors [9]. While there are
clear results for the use of cannabinoids to treat astrocytomas, the
requirement of cannabinoid receptors in mediating this therapeu-
tic effect is still unproven [10]. In fact, evidence suggests that high
concentrations of cannabinoids may induce biological effects,
including the induction of apoptosis in cells, independently of CB1
and CB2 receptors [7,11,12,13]. Thus whether CB1 and CB2
receptors, or yet another cannabinoid-like receptor, mediate the
therapeutic effects of cannabinoids toward astrocytomas is still
unclear.
Other unanswered questions are: Why does CB1 and CB2
expression in astrocyomas gradually increase as a function of
cancerous transformation? [14,15] Does this increase in receptor
expression modify the coupling of CB1 and CB2 to signal
transduction pathways in astrocytomas? Does this increase in
receptor expression modify the efficacy of cannabinoids at
inducing apoptosis in astrocytomas? Indeed, while it is known
that CB1 and CB2 couple to ERK1/2, AKT, JNK, p38 and GSK-
3b [8,16,17,18,19], and that both ERK1/2 and AKT mediate the
induction of apoptosis by cannabinoids in astrocytomas
[8,11,18,20], nothing is known about how changes in CB1 and
CB2 expression will modify the coupling of these receptors to each
kinase, and whether the efficacy with which cannabinoids induce
apoptosis is also affected. Answering these questions is important
for the following reasons. Most of the studies reporting
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in heterologous expression systems and the expression level of
these receptors both surpass those reached by endogenously-
expressed receptors and favor promiscuous coupling to effector
proteins. One particularly controversial point stems from the
ability of cannabinoids to induce apoptosis in astrocytomas when
CB1 and CB2 receptors also couple to the pro-survival kinase
AKT. Therefore, it is important to increase our understanding of
how changes in the expression level of CB1 and CB2 will affect the
coupling of these receptors to specific kinases, as well as the
efficacy of cannabinoids at killing astrocytomas.
Here we sought to address the following two questions: Are the
therapeutic effects of cannabinoids toward astrocytomas truly
mediated by CB1 and CB2 receptors? Does the increase in
cannabinoid receptor expression known to occur in malignant
astrocytomas determine the efficacy of cannabinoids at killing
these tumors? To answer these questions, we generated astrocy-
toma subclones that express low, medium and high levels of either
CB1 or CB2, and studied the ability of the cannabinoid agonist
CP-55,940 to regulate the activity of various kinases and to induce
apoptosis in these tumor cells.
Results
Astrocytoma Subclones Stably Expressing Set Levels of
Either CB1 or CB2 Receptors
To determine whether the expression level of CB1 or CB2
receptors dictate cannabinoid-mediated responses in astrocytomas,
we sought to use heterologous gene expression technology to drive
the expression of these receptors to precise levels in an astrocytoma
cell line that normally lacks these receptors. Specifically, we found
that the murine delayed brain tumor (DBT) cell line expresses
neither CB1 nor CB2 receptors (Table 1). Thus we transfected
these cells with IRES constructs containing the gene that encodes
either CB1 or CB2 receptors in tandem with the gene encoding
eGFP, and used FACS to select for the cells that had stably
incorporated the construct (see Experimental Procedures). Using
this approach, we obtained 27 CB1-expressing DBT subclones and
49 CB2-expressing DBT subclones. We then randomly selected 24
subclones (twelve CB1 and twelve CB2) and performed qPCR to
find out the relative expression level of CB1 and CB2 receptor
mRNA in each single cell subclone (Table S1). Based on these
data, we then focused our experiments on three CB1 subclones
and three CB2 subclones that expressed relatively low, medium
and high levels of receptor mRNA (Table 1). Please note that all
CB1-expressing DBT cells were still devoid of CB2 receptor
mRNA, and vice versa. Quantification of CB1 and CB2 receptor
proteins by radioligand binding showed a correlation between the
relative level of mRNA encoding each receptor and the
corresponding protein expression level as expressed by the Bmax
value (Table 1). Here it is worth noting that the expression level of
CB1 and CB2 receptors in the CB1-mid and the CB2-mid
subclones, respectively, lie well within the range of their levels
when endogenously expressed by various cell lines and tissues
[21,22]. Thus, we generated DBT subclones that stably express set
levels of either CB1 or CB2 receptors, with expression levels that lie
within the range of what is found for cells endogenously expressing
these receptors.
Independent of Expression Levels, CB1 and CB2 Receptors
Similarly Regulate ERK1/2 Signaling
Because previous studies performed on astrocytoma cell lines
have implicated ERK1/2 signaling in the therapeutic actions of
cannabinoids [23], we sought to determine whether different
expression levels of CB receptors would affect their coupling to
this signal transduction pathway. To do so, we treated each
subclone with CP-55,940 (1 mM, maximally efficacious con-
centration [17,24]) and measured ERK1/2 phosphorylation by
Western blot analysis. We found that CP-55,940 induced a
significant increase in ERK1/2 phosphorylation above vehicle-
treated controls in all six subclones (Figure 1a). All these
responses were receptor-mediated since they were significantly
attenuated by either the CB1 antagonist SR141716A, or the
CB2 antagonist SR144528, respectively (Figure 1a). Further-
more, CP-55,940 did not affect ERK1/2 phosphorylation in
wild-type DBT cells (Figure S1a). The magnitude and kinetics of
CP-55,940-induced ERK1/2 phosphorylation mediated in
each subclone were remarkably similar despite a 10-fold
difference in receptor expression level between the CB1-low
and the CB1-high subclones, and between the CB2-low and the
CB2-high subclones (Figure 1b,c). The only differences that we
noted between CB1-a n dC B 2-mediated regulation of ERK1/2
phosphorylation were that CP-55,940 induced a slightly slower
and sustained increase in ERK1/2 phosphorylation in CB1-
expressing subclones (peak at 5 min returning to basal by
20–30 min) compared to CB2-expressing subclones (peak at
3 min returning to basal by 10–20 min) (Figure 1b,c). These
results show that CB1 and CB2 receptors heterologously
expressed in DBT cells are functional for they regulate
ERK1/2 phosphorylation. They also show that the efficacy of
this regulation is largely independent of receptor expression
levels and receptor subtype.
The Expression Level of CB1 and CB2 Receptors Dictates
Their Ability to Regulate AKT, JNK and p38 Signaling
CB1 and CB2 receptors have been shown to regulate a plethora
of kinases, including AKT, JNK, p38 and GSK-3b
[8,16,17,18,19]. Thus we sought to assess if CB1 and CB2
heterologously expressed in DBT cells also regulate these four
kinases. To do so, we treated all DBT subclones with CP-55,940
Table 1. Expression levels of CB1 and CB2 receptors in wild-
type and selected DBT subclones.
Nomenclature subclones qPCR Radioligand binding
CB1 CB2 Bmax kd
(cycle threshold) (pmol/mg) (nM)
Wild type WT no ct no ct no binding -
CB1-low E3 22.4 no ct 0.2 0.8
CB1-mid E7 17.7 no ct 0.7 0.8
CB1-high E5 14.7 no ct 1.3 0.7
CB2-low 2G5 no ct 24.1 0.3 0.8
CB2-mid 2H1 no ct 18.0 0.6 0.4
CB2-high 1D6 no ct 14.0 2.3 0.6
Wild-type DBT cells and DBT subclones stably expressing cannabinoid receptors
were expanded in 10 cm dishes, and either their RNA extracted for qPCR
analysis of CB1 and CB2 mRNA levels, or homogenized for radioligand binding
analysis of CB1 and CB2 receptor protein levels. mRNA levels are expressed as
cycle threshold (ct) value from qPCR performed with Taqman probes. Values
represent mean of three independent determinations. Receptor protein level is
expressed as Bmax values from radioligand binding experiments performed with
[
3H]CP-55,940. kd values were also determined and show consistent low
nanomolar affinities. Values represent mean of 3–5 independent
determinations.
doi:10.1371/journal.pone.0008702.t001
Cannabinoids and Apoptosis
PLoS ONE | www.plosone.org 2 January 2010 | Volume 5 | Issue 1 | e8702and assessed the phosphorylation state of these kinases using a
Luminex multiplexed immunoassay system.
With regard to AKT, three points are noteworthy. First, the CP-
55,940-induced increase in AKT phosphorylation correlated with
receptor expression levels (Figure 2a). Specifically, CP-55,940 did
not significantly increase AKT phosphorylation in the CB1-low
subclone, which expresses the lowest level of receptor of all six
subclones that we have selected; it induced a small, but significant
increase in AKT phosphorylation in CB2-low and CB2-mid, which
express slightly more receptors than the CB1-low subclone; and it
induced the most pronounced increase in AKT phosphorylation in
CB1-mid, CB1-high and CB2-high subclones (see Table 1 for Bmax
values). Second, all responses were mediated by cannabinoid
receptors since they were antagonized by either SR141716A or
SR144528, respectively, and CP-55,940 did not increase AKT in
wild type DBT cells (Figures 2a and S1b). Third, there was a clear
difference in the kinetics of AKT activation linked to either CB1 or
CB2 receptors. Specifically, while the response obtained in the
CB1-high subclone peaked at 3 min and returned to the basal level
at 5 min, the response measured in the CB2-high clone remained
above 250% of basal during the entire 30 min of the incubation
period (Figure 2b,c).
With regard to JNK and p38, CP-55,940 induced a small (150–
170% of basal) but significant increase in the phosphorylation state
of these kinases only in the CB2-high clone that also lasted
throughout the 30 min incubation period (Figure S2a,b). With
regard to GSK-3b, CP-55,940 did not significantly affect the
phosphorylation state of this kinase in any of the subclones
throughout the 30 min incubation time period (data not shown).
Taken together, these results suggest that the different
expression levels of CB1 and CB2 receptors determine the efficacy
with which cannabinoids regulate AKT, JNK and p38 signaling.
They also suggest that CB1 and CB2 receptors differentially couple
to these kinases.
Only Activation of CB1 Receptors Expressed at Low Levels
in DBT Cells Leads to Apoptosis: Involvement of ERK1/2
Several studies suggest that activation of CB1 or CB2 is sufficient
to induce apoptosis in astrocytomas [8,14], whereas other studies
suggest that only high concentrations of cannabinoids kill
astrocytomas and furthermore, independently of cannabinoid
receptor activation [7,11,12,13]. We directly tested these possibil-
ities by treating the DBT subclones, as well as wild-type DBT cells,
with CP-55,940 at either 1 mM (receptor-mediated) or 10 mM
(receptor-independent). To assess for cell viability, we used WST-
1, an indicator of mitochondrial activity. We found that 1 mM CP-
55,940 induced ,50% cell death in the CB1-low DBT subclone,
whereas 10 mM CP-55,940 induced 35–90% cell death in wild
type DBT cells and all six subclones (Figure 3a). This result
suggests that only the activation of CB1 receptors expressed at low
levels in DBT cells leads to significant receptor-dependent killing
of these cells. Two additional sets of results support this conclusion.
First, SR141617A blocked the 1 mM CP-55,940-induced killing of
the CB1-low DBT cells, whereas this antagonist did not affect the
10 mM CP-55,940-induced cell death of wild type DBT cells
(Figure 3b). Second, CP-55,940 killed CB1-low DBT cells with an
EC50 of 0.56 mM, whereas this compound induced the cell death
of wild type DBT cells with an EC50 of 5 mM (Figure 3c).
Interestingly, when comparing the effect of 1 mM CP-55,940 on
CB1-low DBT cells to the effect of 10 mM CP-55,940 on wild-type
DBT, we found that the 10 mM CP-55,940-induced killing of wild-
type DBT (receptor-independent) is more rapid than the CB1-
mediated cell death (Figure 3d).
Figure 1. Activation of CB1 and CB2 receptors increases ERK1/
2 phosphorylation in all DBT subclones. DBT subclones stably
expressing cannabinoid receptors were expanded in 24-well plates,
incubated with CP-55,940 (CP, 1 mM), and ERK1/2 phosphorylation
quantified by Western blot analysis. (a) CB1-a n dC B 2-expressing
subclones were incubated with CP for 5 and 3 min, respectively (white
bars). When testing the effect of antagonists, cells were pretreated
with SR141716A (5 mM) and SR144528 (3 mM) added 10 min before CP
(black bars). (b,c) Kinetics of CP-induced increase in ERK1/2 phosphor-
y l a t i o ni nC B 1-low, CB1-high, CB2-low and CB2-high subclones.
Data=mean6s.e.m. of 6–8 independent experiments expressed as
% of vehicle (i.e. level of ERK1/2 phosphorylation when treated with
vehicle, i.e. 0.1% DMSO. Note that basal ERK1/2 phosphorylation did
not vary significantly over time (Figure S1a). In (a),( * )=p ,0.05 and
(**)=p,0.01 significantly different fro mt h er e s p o n s ei nt h ep r e s e n c e
of inhibitor, ANOVA followed by Bonferroni’s post-test. In (b,c),( * )a n d
(#)=p,0.05, and (**) and (##)=p,0.01 significantly different from
vehicle at corresponding time point, ANOVA followed by Bonferroni’s
post-test.
doi:10.1371/journal.pone.0008702.g001
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cannabinoid receptor-independent killing of DBT cells were
apoptotic in nature. Specifically, we treated CB1-low DBT cells
with 1 mM CP-55,940 and wild type DBT cells with 10 mM CP-
55,940, and assessed for propidium iodide and annexin V staining
(to assess for cell permeability and apoptosis, respectively). Figure 4
shows that after five days, cell death by apoptosis was induced in
78% of the wild-type DBT cells treated with 10 mM CP-55,940
compared to 48% of the CB1-low DBT cells treated with 1 mM
CP-55,940. Furthermore, in agreement with the data we have
obtained with WST-1, 10 mM CP-55,940 killed more wild-type
DBT cells by apoptosis (27%) 3 days after treatment compared to
CB1-low DBT cells treated with 1 mM CP-55,940 (15%) (Figure 4).
Together, these data show that both the CB1-dependent and the
cannabinoid receptor-independent killing of DBT cells are due to
apoptosis, but that these processes occur with slightly different time
courses.
Because we found that 1 mM CP-55,940 increases ERK1/2
signaling in CB1-low DBT cells without affecting the AKT, JNK,
p38 and GSKb signaling pathways, and one study suggested that
ERK1/2 mediates the apoptotic properties of cannabinoids on
astrocytomas [8], we then tested if inhibiting ERK signaling would
affect the CB1-mediated and the cannabinoid receptor-indepen-
dent killing of DBT cells. Thus, we pretreated CB1-low and wild-
type DBT cells with the ERK kinase kinase inhibitor PD98059
before applying either 1 or 10 mM CP-55,940. We found that both
responses were partially prevented by this inhibitor (Figure 3b).
Thus both the CB1-dependent and the cannnabinoid receptor-
independent induced apoptosis of DBT cells rely on ERK
signaling.
Together, these results show that cannabinoid concentrations
known to activate CB1 and CB2 receptors (here 1 mM) induce
apoptosis in astrocytomas only when these cells express low levels
of CB1 receptors, and that this response is mediated through ERK
signaling. Conversely, high concentrations of cannabinoids known
to bypass cannabinoid receptors (here 10 mM) induce apoptosis in
all DBT subclones, a mechanism that also depends on ERK
signaling.
CB1- and CB2-Induced Apoptosis of DBT Cells Is
Uncovered When AKT Is Inhibited
Because increased AKT signaling promotes cell survival [25],
we reasoned that activation of this pathway by CB1 and CB2
receptors expressed at mid and high levels might explain why
1 mM CP-55,940 was unable to induce apoptosis in DBT
subclones. To test this hypothesis, we treated the six subclones
of DBT cells with 1 mM CP-55,940 in combination with Inhibitor
X, a cell-permeable inhibitor of AKT [26]. Using the WST-1
assay, we found that while this inhibitor had no effect by itself on
cell viability, it uncovered the ability of 1 mM CP-55,940 to kill all
the DBT subclones that were normally resistant, with the most
pronounced response occurring in CB2-low DBT cells (Figure 5a).
This latter response was due to apoptosis, since 76% of the cells
stained positively for annexin V when measured five days after co-
application of 1 mM CP-55,940 and Inhibitor X (Figure 5b). These
results suggest that the coupling of CB1 and CB2 receptors to the
AKT pathway (when these receptors are expressed at mid and
high levels) eliminates the ability of cannabinoids to induce
apoptosis in DBT cells.
Discussion
While many laboratories have reported that cannabinoids
induce apoptosis in various tumor subtypes, including astrocyto-
Figure 2. Activation of CB1 and CB2 receptors differentially
increases AKT phosphorylation in DBT subclones. DBT subclones
stably expressing cannabinoid receptors were expanded in 24-well
plates, incubated with CP-55,940 (CP, 1 mM), and AKT phosphorylation
quantified by Luminex multiplex immunoassay. (a) CB1- and CB2-
expressing subclones were incubated with CP for 5 and 3 min,
respectively (white bars). When testing the effect of antagonists, cells
were pretreated with SR141716A (5 mM) and SR144528 (3 mM) added
10 min before CP (black bars). (b,c) Kinetics of CP-induced increase in
AKT phosphorylation in CB1-low, CB1-high, CB2-low and CB2-high
subclones. Data=mean6s.e.m. of 6 to 8 independent experiments
expressed as % of vehicle (i.e. level of AKT phosphorylation when
treated with vehicle, i.e. 0.1% DMSO. Please note that basal AKT
phosphorylation did not vary significantly over time (Figure S1b). In (a),
(*)=p,0.05 significantly different from the response in the presence of
inhibitor, ANOVA followed by Bonferroni’s post-test. In (b,c), (*) and
(#)=p,0.05, and (**) and (##)=p,0.01 significantly different from
vehicle at corresponding time point, ANOVA followed by Bonferroni’s
post-test. Non-significant (ns).
doi:10.1371/journal.pone.0008702.g002
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therapeutic effect has not yet been demonstrated. This point is
especially relevant when considering that many of these studies
used high concentrations of cannabinoids known to bypass CB1
and CB2 receptor activation. Here we demonstrate that canna-
binoid receptors and ERK1/2 indeed mediate this therapeutic
effect, but only when these compounds are applied at submicro-
molar concentrations and the expression level of these receptors
remains low. Conversely, high concentrations of cannabinoids kill
all astrocytoma subclones independently of CB1,C B 2 and AKT,
yet still through a mechanisms involving ERK1/2. We also show
that increased expression of CB1 and CB2 receptor allows for their
coupling to additional kinases, especially AKT, the result of which
eliminates the ability of cannabinoids to induce apoptosis even
though these receptors still couple to ERK1/2.
One of the most unexpected and interesting findings of our
study is that the coupling of CB1 and CB2 receptors to AKT, JNK
and p38 is dictated by receptor expression levels, whereas their
coupling to ERK1/2 is not. What may be the molecular
mechanism underlying a gradual coupling to AKT, JNK and
p38, while preserving a steady coupling to ERK1/2? Reports on
the molecular mechanisms linking cannabinoid receptors to
various kinases suggest that these receptors activate AKT through
G-proteins, while activating ERK1/2 through EGF receptor
transactivation [27]. Based on these reports, a parsimonious
interpretation of our results would be that the rate limiting step
controlling the efficacy of cannabinoids at stimulating AKT lies in
the cannabinoid receptors themselves, whereas the rate limiting
step controlling the efficacy of cannabinoids at stimulating ERK
lies in EGF receptors, the expression of which is likely to remain
constant in the DBT subclones that we generated. Our results may
have broader implications when considering the therapeutic
efficacy of cannabinoids toward other neuropathologies. For
example, epileptic seizures and cerebral ischemia lead to a 3–4
fold increase in the expression of neuronal CB1 receptors, a
response thought to constitute a protective mechanism [28,29],
Figure 3. CP-55,940 kills DBT cells via cannabinoid receptor-dependent and -independent mechanisms. Wild-type (wt) DBT cells and
DBT subclones stably expressing cannabinoid receptors were expanded in 24-well plates, incubated with CP-55,940 (CP) at either 1 mM (receptor
mediated) or 10 mM (receptor independent), and cell viability was assessed by quantifying WST-1 conversion. (a) Five days after treatment, only CB1-
low DBT cells showed significant sensitivity to CP at 1 mM, whereas all subclones were sensitive to CP at 10 mM. Data represent means6s.e.m. of 5–9
independent experiments in triplicate. (b) Only the pretreatment of CB1-low DBT cells with SR141617A (5 mM) prevented the CP-induced killing,
whereas pretreatment with PD 98059 (PD, 10 mM) significantly reduced both the CP 1 mM and CP 10 mM induced toxicity in CB1-low and wild-type,
respectively. Data represent means6s.e.m. of 3–5 independent experiments in triplicate. (c) Dose-response and (d) kinetics of CP-induced killing of wt
and CB1-low DBT cells. Data represent means6s.e.m. of 3–9 independent experiments in triplicate. All results are expressed as % of WST-1
measurements in corresponding cells treated with vehicle (0.1% DMSO) for the indicated time point. In (a), (*)=p,0.05 and (**)=p,0.01 significantly
different from the viability in the presence of vehicle only, ANOVA followed by Bonferroni’s post-test. In (b), (**)=p,0.01 significantly different the
viability after treatment with either 1 or 10 mM CP, ANOVA followed by Bonferroni’s post-test. In (c), (**) and (##)=p,0.01 significantly different
from the viability in the presence of vehicle only, ANOVA followed by Bonferroni’s post-test. In (d),( #)=p,0.05, and (**) and (##)=p,0.01
significantly different from the viability in the presence of vehicle only at corresponding time point, ANOVA followed by Bonferroni’s post-test.
doi:10.1371/journal.pone.0008702.g003
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PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8702Figure 4. Time course of the apoptotic response induced by CP-55,940 in wild-type and CB1-low DBT cells. (a,b) Wild-type (wt) DBT
cells and (c,d) CB1-low DBT cells were expanded in 6-well plates, incubated with CP-55,940 (CP) at 10 and 1 mM, respectively, and apoptosis assessed
by quantifying propidium iodine (PI) and annexin V fluorescence by FACS after 1, 3, and 5 days. Shown are representative results, with values within
each quadrant=mean of 3–5 independent experiments.
doi:10.1371/journal.pone.0008702.g004
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expression of neuronal CB1 receptors, a decrease thought to
participate in the pathogenesis of this neurodegenerative disease
[30,31]. Based on the results that we report here, one would
predict that up- or down-regulation of neuronal CB1 receptor
expression should not affect the efficacy of cannabinoids at
stimulating ERK signaling, whereas it might dictate their ability to
modulate the activity of the prosurvival kinase AKT. Thus our
study is the first to suggest that changes in cannabinoid receptor
expression levels will affect only certain types of signal transduc-
tions pathways, several of which are clearly involved in the control
of cell survival and death. This result has implications when
considering the efficacy of cannabinoids at treating astrocytomas
of increasing malignancy, but also when considering other
neuropathologies associated with changes in cannabinoid receptor
expression.
An additional noteworthy result was the differential coupling of
CB1 and CB2 receptors to AKT. Indeed, cells expressing similar
ranges of CB1 and CB2 receptors (CB1-mid to CB1-high being
between 0.7 and 1.3 pmol/mg, and CB2-mid to CB2-high being
between 0.6 and 2.3 pmol/mg) exhibited a clearly different
coupling to this prosurvival kinase. How might the same agonist
acting at CB1 and CB2 differentially stimulate this kinase? CB1 and
CB2 exhibit significant disparities in their amino acid sequence,
particularly in their intracellular domains which interact with G
proteins and effector proteins. Indeed, upon their molecular
identification, it was evident that while both receptors exhibit
similar pharmacological profiles, they only exhibited an overall
44% amino acid identity [32]. We preformed a sequence
alignment between mouse CB1 and mouse CB2, and highlighted
in red the sequence motifs located in the intracellular loops that
may account for the differential interactions with G proteins and
found that these regions exhibit a much diminished 29% similarity
(Figure S3). In agreement with this reduced amino acid similarity
in intracellular sequences, a recent study showed that the binding
of the same agonist to either CB1 or CB2 receptors leads to
differential activation of G-proteins [33]. Another possible
explanation of how the same agonist engaging either CB1 or
CB2 receptors might differentially activate a signal transduction
mechanism is based on studies that were obtained with ‘‘ligand-
assisted protein structure’’ (LAPS) analysis [34,35]. Here the
positioning of the tricyclic ring of a specific cannabinoid agonist,
AM841 (a close analogue of CP-55,940), within the binding
pockets of either CB1 or CB2 receptors has been shown to vary
considerably, from being parallel to the transmembrane helices in
CB1 to being perpendicular to the transmembrane helices in CB2
[34,35]. Since agonists engaging the binding pocket of a GPCR
will favor a specific R* activation conformation, the same agonist
differentially engaging the binding pocket of either CB1 or CB2
receptors will likely lead to distinct R* conformations for these
receptors, and thus differential G protein coupling. Hence, both
sequence disparities in the intracellular loops and the precise
positioning of a cannabinoid ligand within the binding pocket of
CB1 and CB2 receptors could account for the differential
activation of a specific kinase.
When considering cannabinoids to treat astrocytomas, many
have attempted to isolate the non-psychotropic therapeutic effects
ascribed to CB2 receptor activation, while eliminating the
psychotropic and addictive properties ascribed to CB1 receptor
activation [14]. However, since cannabinoids have outstanding
LD50 values (mainly because cannabinoid receptors are barely
expressed in brains regions that control vegetative functions) [36],
the treatment of tumors with high concentrations of cannabinoids
should not be overlooked. In fact, stereotaxic injection of high
Figure 5. Inhibition of AKT signaling confers sensitivity of
cannabinoid receptor-expressing DBT cells to cannabinoid-
dependent cytotoxicity. (a) Wild-type (wt) DBT cells and DBT
subclones stably expressing cannabinoid receptors were expanded in
24-wellplates,incubatedwithCP-55,940(CP)at1 mM(r ec ep to r- m ed i at ed )
without or with Inhibitor X (5 mM added 10 min before CP), and cell
viability was assessed after 5 days by quantifying WST-1 conversion. Data
represent means6s.e.m. of 3–9 independent experiments in triplicate.
(*)=p,0.05 and (**)=p,0.01 significantly different from the viability in
the presence of vehicle only, ANOVA followed by Bonferroni’s post-test.
(b) wt and CB2-low DBT cells were expanded in 6-well plates, incubated
with CP at 1 mM (receptor-mediated) without or with Inhibitor X (5 mM
added 10 min before CP), and the apoptotic response assessed after 5
days by propidium iodine (PI) and annexin V staining by FACS after 1, 3,
and 5 days. Shown are representative results, with values within each
quadrant=mean of 3–5 independent experiments.
doi:10.1371/journal.pone.0008702.g005
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of C6 astrocytomas inoculated into rodent brains without affecting
healthy surrounding tissue or inducing overt adverse effects [8].
Since stereotaxic injection of chemotherapeutic compounds
directly into human brain tumor masses constitutes a routine
approach for neurosurgeons, high concentrations of cannabinoids
can easily be delivered by this technique [9]. There are two
additional advantages to delivering high concentrations of
cannabinoids directly into the tumor mass. Malignant transfor-
mation of astrocytomas is associated with an increase in
cannabinoid receptor expression [14,15] and we show here that
this increase in expression precludes the use of low concentrations
of cannabinoids known to activate these receptors. Conversely,
local injection of high concentrations of cannabinoids will induce
apoptosis in all astrocytoma subclones (independently of CB1 and
CB2 receptor expression), which constitutes an asset when
considering the phenotypic heterogeneity that astrocytomas adopt
during malignant transformation [37,38]. Thus, our results suggest
that high concentrations of cannabinoids constitute the preferred
regimen for neurosurgeons to use when treating malignant
astrocytomas with this class of compounds.
One outstanding question that is raised by our study is: what
constitutes the molecular target that is engaged by high
concentrations of cannabinoids, a target that also leads to
ERK activation and induction of apoptosisinastrocytomas? One
possibility is another GPCR, several of which have recently been
shown to be engaged by high concentrations of cannabinoids,
including CP-55,940 [39]. One obvious candidate is GPR55
[40], although this receptor can be ruled out in the context of our
studies since we found no evidence for the presence of GPR55
m R N Ai nD B Tc e l l s( a sa s s e s s e db yR T - P C Ra n dq P C R ,d a t a
not shown). Thus, while the molecular identification of this
target remains to be determined, its identification will most
certainly raise a lot of interest for research aimed at developing
novel therapeutic approaches to treat astrocytomas and other
tumors.
In conclusion, our study provides the first evidence for the
differential activation of AKT, p38 and JNK by a highly
efficacious cannabinoid agonist, CP-55,940, engaging either CB1
or CB2 receptors expressed at different levels. This shift in
coupling precludes the use of cannabinoids at submicromolar
concentrations as pro-apoptotic therapeutics, unless AKT is
concomitantly inhibited. Our results also suggest that high
concentrations of cannabinoids are preferable for efficacious
treatment of malignant astrocytomas, because these concentra-
tions bypass CB1 and CB2 receptor activation and induce
apoptosis in all astrocytoma cell subpopulations.
Materials and Methods
Drugs
Tritium-labeled and unlabeled CP 55,940 ((2)-cis-3-[2-hydroxy-
4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohex-
anol), SR141716A (5- (4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-N-(1-piperidyl)-1H-pyrazole-3-carboxamide), and SR144528
(5- (4-chloro-3- methyl- phenyl)-1- [(4- methylphenyl)methyl]- N-
(1,3,3- trimethylnorbornan- 2- yl)- pyrazole- 3- carboxamide) were
provided by the National Institute of Drug Abuse Drug Supply
Program (RTI, Research Triangle Park, NC). PD 98059 and
Inhibitor X were from CalBiochem (San Diego, CA).
Generation of DBT Subclones Expressing mCB1 and mCB2
mCB1 and mCB2 were PCR-cloned from an existing construct
using the following primers, respectively: forward, 59-gcgaattc-
atgaagtcgatcttagacggccttgc-39 and reverse, 59-gcggatcctcacagag-
cctcggcagacgtgtctg-39; forward, 59-gcgaattcatggagggatgccgggaga-
cagaagtg-39 and reverse, 59-gcggatcctaggtggttttcacatcagcctctg-39.
Please note that these receptors are not linked to any molecular
tag, because such additions often affect the coupling of GCPRs to
their signal transduction pathways. Amplicons were digested with
EcoR I and BamH I, and ligated into the corresponding multiple
cloning site of the pIRES2-EGFP vector (BD Biosciences
Clontech, Mountain View, CA). The murine delayed brain tumor
(DBT) cell line, which was originally developed using the Schmidt-
Ruppin strain of Rous sarcoma virus inoculated into an adult
CDF1 mouse brain [41], was expanded at 37uC with 5% CO2 in
10 cm Falcon dishes (BD Biosciences, San Jose, CA) containing
10 ml of culture media: DMEM+GlutaMAX
TM-I (Gibco, Carls-
bad, CA) supplemented with fetal bovine serum (FBS, 10%),
HEPES (10 mM) and penicillin/streptomycin (100 units/ml and
100 mg/ml, respectively). Once cells reached ,70% confluence,
they were transfected with either pIRES2-EGFP-mCB1 or
pIRES2-EGFP-mCB2 using SuperFect (QIAGEN, Valencia,
CA) according to the manufacturer’s instructions. Three days
after transfection, the resulting positive cells (,5% of fluorescent
green cells) were isolated using fluorescence assisted cell sorting
(FACS, BD FACS Vantage SE) (Figure S4). These enriched cells
were put back into culture for an additional 7 days of selection and
expanded in media containing G418 (10 ml per 10 cm culture
dishes). Cells that survived were isolated again by FACS, and
similarly reselected and expanded for three additional rounds to
ensure for the stability of each clone. In the final round, we used
FACS to isolate single eGFP-positive cells and seeded them into
Costar 96-well plates (0.2 ml per well, changing the media every 3–
5 days). Three to six weeks later, all single-cell subclones that had
expanded were harvested. Please note that both the fluorescence
emitted by these single-cell subclones and the receptor expression
levels were stable for at least 20 passages, showing that the shuttled
plasmid had been stably incorporated in these cells.
qPCR and Radioligand Binding
Cells (10
6) were expanded in 10 cm dishes using 10 ml culture
media. Once they reached ,70% confluence, they were rinsed
with PBS and kept for an additional 24 hrs in serum-deprived
media, which is composed of DMEM+GlutaMAX
TM-I supple-
mented with fatty acid free bovine serum albumin (0.1%, BSA,
Sigma-Aldrich, St. Louis, MO) and insulin-transferin-sodium
selenite liquid media (16, ITS, Sigma-Aldrich). For qPCR, media
was removed and cells washed once with 10 ml PBS, then cells
were scraped and total RNA isolated using RNeasy extraction kit
(QIAGEN) according to the manufacturer’s instructions. The
following primer and TaqMan probe sequences were generated
using Primer Express (Perkin-Elmer Applied Biosystems, Foster
City, CA): mCB1 forward, 59-cacaagcacgccaataacaca-39, reverse,
59-acagtgctcttgatgcagctttc-39, probe, 59-(gccagcatgcacagggccgcg)-
39; mCB2 forward, 59-gaacatggccgtgctctatattatc-39, reverse, 59-
gaacaggtacgagggctttctg-39, probe, 59-(ctgtcctcccggcggctccg)-39.
Total RNA from each sample (2.5 ng) was reverse transcribed in
the same 10 ml quantitative PCR reaction mix using the Brilliant
Single-Step Quantitative RT-PCR Core Reagent Kit (Stratagene,
La Jolla, CA). Combined reactions were carried out on a
Stratagene Mx3000P Real-Time Detection System using the
following protocol: 30 min single-strand synthesis reaction at
45uC; 40-cycle, two-step PCR amplification (15 sec at 95uC
followed by 1 min at 56uC). Duplicate reactions with and without
reverse transcriptase were run for each sample. For radioligand
binding, media was removed and cells washed once with 10 ml
PBS. Cells were scraped in 1 ml buffer (50 mM Tris-HCl, 3 mM
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using PRO200 tissue homogenizer (PRO Scientific, Oxford, CT).
Crude membrane preparations were generated by centrifugation
of cell homogenates for 20 min at .10,0006g. Cell pellets were
resuspended in buffer containing BSA (0.1%, fatty acid free) and
50 mg protein added to siliconized glass tubes for assay.
Concentrations of [
3H]CP-55,940 between 0.1 and 10 nM were
used for saturation experiments, and 1 mM CP-55,940 was used to
determine specific binding. After 1 hr incubation at 30uC,
reactions were stopped by rapid filtration over GF/B glass fiber
filters on a 24-well M-24T Brandel cell harvester (Brandel,
Gaithersburg, MD) and washed 3 times with ice-cold binding
buffer containing BSA. Radioactivity on filters was measured using
scintillation counter.
Quantifying the Phosphorylation of ERK1/2, AKT, JNK,
p38 and GSKb
Cells were expanded in Costar 24-well plates (10
5 cells per well)
in culture media (0.5 ml per well). Once they reached ,70%
confluence, they were rinsed with PBS and kept for an additional
24 hrs in serum-deprived media, at which time point drugs or
vehicle (DMSO, 0.1%) prepared in 50 ml serum-deprived media
were directly added to each well for the corresponding number
of minutes. We chose to directly administer the drugs to cell
culture media instead of replacing the media to avoid stress-
induced increases in basal kinase phosphorylation (Figure S1).
To quantify Erk phosphorylation, reactions were stopped by
removing the media and adding NuPAGEH LDS sample buffer
(300 ml, Invitrogen, Carlsbad, CA) supplemented with 2-
mercaptoethanol (1%). An aliquot of each sample (20 ml) was
loaded onto NuPAGEH 4–12% Bis-Tris pre-cast gels (Inivtrogen)
and electrophoresed according to the manufacturer’s instruc-
tions. Gels were electrophoretically transferred to P-nitrocellu-
lose membrane (Millipore, Billerica, MA) and blocked in LiCOR
blocking buffer (LiCOR, Lincoln, NE) for 1 hr at 25uC.
Membranes were then incubated in blocking buffer containing
rabbit anti-phospho-p44/42 antibody (1:1000, Cell Signaling
Technology, Inc., Danvers, MA) for 1 hr at 25uC. Membranes
were washed 3 times with Tris (50 mM) buffered saline
containing 0.1% Tween-20 (TBS-T). Membranes were then
incubated in blocking buffer containing donkey anti-rabbit
antibody conjugated to IRDye 800 (1:7500, Rockland Immu-
nochemicals, Inc., Gilbertsville, PA) for 1 hr at 25uC. Mem-
branes were washed 3 times with TBS-T. The fluorescence
intensity of each band was quantified using the LiCOR Odyssey.
T oq u a n t i f yA K T ,J N K ,p 3 8a n dG S K b phosphorylation,
reactions were stopped by addition of NP40 cell lysis buffer
(100 ml, Invitrogen). Substrate phosphorylation was quantified
using a Biosource Multiplex Bead Immunoassay kit (Invitrogen)
according to the manufacturer’s instructions and using a
Luminex 100
TM instrument (Luminex, Austin, TX). Note that
the basal phosphorylation state of these kinases in each subclone
did not change significantly when the cells were incubated over
the 30 min time-period of the incubation with vehicle only
(Figure S1).
Quantification of Cell Viability and Apoptosis by WST-1,
Propidium Iodine (PI) and Annexin V
Cells were expanded in 24-well plates (10
5 cells per well) in
culture media (0.5 ml per well). Once they reached ,70%
confluence, they were rinsed with PBS and kept for an additional
24 hrs in serum-deprived media, at which time drugs or vehicle
(DMSO, 0.1%) prepared in 50 ml serum-deprived media were
directly added to each well. After 1, 3, or 5 days, cell viability was
assessed using the Cell Proliferation Reagent WST-1 (Roche,
Indianapolis, IN). Briefly, WST-1 reagent (50 ml) was added to
each well for 4 hrs at 37uC with 5% CO2, and then WST-1
products were read at 450 nm using Packard SpectraCount
TM.
Apoptosis was assessed using PI and annexin V (Pacific Blue
TM,
Invitrogen). Briefly, cells were detached using trypsin, rinsed with
25uC PBS and resuspended to a density of 10
6 cells per ml of
annexin-binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM
CaCl2, pH 7.4). PI (100 ng) and annexin V were added to 100 ml
of cell suspension and incubated at 25uC for 30 min. Additional
annexin-binding buffer was added (400 ml) and samples were
sorted (10,000 events) on a LSR II flow cytometer (BD
Biosciences, San Jose, CA) and the data analyzed using FlowJo
(Tree Star, Inc., Ashland, OR).
Data Analysis
Statistics, Bmax,k d, and EC50 values were calculated using
Prism.
Supporting Information
Figure S1 Kinase activity in wild-type.
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